<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458146</url>
  </required_header>
  <id_info>
    <org_study_id>MM-093-01-201</org_study_id>
    <nct_id>NCT00458146</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MM-093 is safe and effective in the&#xD;
      treatment of RA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and tolerability of 60 mg of MM-093 in patients who have active RA&#xD;
      despite MTX background therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of MM-093 using ACR20 response rate</measure>
    <time_frame>After three months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of MM-093 using DAS-28 and EULAR</measure>
    <time_frame>After three months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-093</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-093</intervention_name>
    <description>60mg MM-093/week as a subcutaneous injection for 3 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet American College of Rheumatology (ACR) criteria for RA.&#xD;
&#xD;
          -  Have active RA consisting of &gt; or equal to 6 tender joints and &gt; or equal to 6 swollen&#xD;
             joints and one of the following:CRP or ESR levels of ULN&#xD;
&#xD;
          -  Have an ACR functional class of I-III.&#xD;
&#xD;
          -  Have had RA for at least 6 months.&#xD;
&#xD;
          -  Had disease onset at &gt; 16 years of age.&#xD;
&#xD;
          -  Aged 18 - 80 years.&#xD;
&#xD;
          -  Currently being treated with a stable, well tolerated weekly dose of MTX between 10-25&#xD;
             mg for at least 6 consecutive prior to screening visit.&#xD;
&#xD;
          -  Currently being treated with folic/folinic acid in conjunction with their MTX&#xD;
             treatment.&#xD;
&#xD;
        (Note: Patients may begin folic/folinic acid treatment after their screening visit, but&#xD;
        must remain on stable dose for two weeks before undergoing the Day 1 assessments.)&#xD;
&#xD;
          -  Willing to remain on a constant, weekly dose of MTX and folic/folinic acid through out&#xD;
             the duration of the study.&#xD;
&#xD;
          -  Understand, sign, and date the written, voluntary informed consent form at the&#xD;
             screening visit prior to any protocol - specific procedures being performed.&#xD;
&#xD;
          -  Be able and willing to comply with study visits and procedures per protocol.&#xD;
&#xD;
          -  Women of childbearing potential must use a medically acceptable means of birth control&#xD;
             in an effective manner and agree to continue its use during the study and for 4 weeks&#xD;
             after the last dose of study drug. Women who have had a complete surgical hysterectomy&#xD;
             or are postmenopausal (absence of menstrual period for at least one year or &gt; 52 years&#xD;
             old) are exempt from this requirement. Medically acceptable forms of birth control&#xD;
             include oral contraceptives, injectable or implantable methods, intrauterine devices,&#xD;
             tubal ligation (if performed more than 1 year before screening), or properly used&#xD;
             barrier contraception. Additionally, the use of condoms is suggested as an adjunct to&#xD;
             the methods previously addressed to protect against sexually transmitted diseases and&#xD;
             to provide additional protection against accidental pregnancy.&#xD;
&#xD;
          -  Sexually active men must agree to use a medically acceptable form of contraception&#xD;
             during the study and continue for 4 weeks after the last dose of study drug.&#xD;
&#xD;
          -  Able to store patient kit/cooler containing drug in a refrigerator at home.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient will be excluded if any of the following prior medications are currently being&#xD;
             used or have used within the designated time interval before the screening visit:&#xD;
&#xD;
               1. Any B - cell or antibody depleting therapy , including plasmaphoresis or Prosorba&#xD;
                  columns (6 months)&#xD;
&#xD;
               2. Leflunomide, Adalimumab (Humira)(3 months)&#xD;
&#xD;
               3. Investigational biologics (2 months)&#xD;
&#xD;
               4. Infliximab (Remicade) (2 months)&#xD;
&#xD;
               5. Cyclosporine, sulphasalazine, auranofin, intramuscular gold, azathioprine,&#xD;
                  D-penicillamine, tacrolimus (6 weeks)&#xD;
&#xD;
               6. Investigational small molecules (e.g. NSAIDS or Cox-2 inhibitors)(4 weeks)&#xD;
&#xD;
               7. Use more than 10mg/day of prednisone or equivalent (4 weeks)&#xD;
&#xD;
               8. Bolus intramuscular/intravenous (IM/IV) treatment with corticosteroids (&gt;20 mg&#xD;
                  prednisone or equivalent)(4 weeks)&#xD;
&#xD;
               9. Intra-articular corticosteroid injection (4 weeks)&#xD;
&#xD;
              10. Etanercept (Enbrel) (4 weeks)&#xD;
&#xD;
              11. Anakinra (Kineret) (2 weeks)&#xD;
&#xD;
              12. Use of more than one NSAID (current)&#xD;
&#xD;
              13. Dose of NSAID greater than maximum recommended dose in the product information&#xD;
                  (current)&#xD;
&#xD;
          -  Significant concurrent medical diseases including:&#xD;
&#xD;
               1. Cancer, or a history of cancer (other than successfully resected cutaneous basal&#xD;
                  and squamous cell carcinoma) within 5 years before the screening visit.&#xD;
&#xD;
               2. Any condition for which participation in this study is judged by the physician to&#xD;
                  be detrimental to the patient, such as history of significant or unstable&#xD;
                  cardiac, pulmonary, gastrointestinal, neurological, or psychiatric disease, or a&#xD;
                  DMARD-related severe, potentially life threatening AE.&#xD;
&#xD;
               3. Significant ongoing infection requiring systemic antibiotic, antifungal,&#xD;
                  antiviral, or anti-myobacterial therapy.&#xD;
&#xD;
          -  Autoimmune or connective tissue disorder other than rheumatoid arthritis (e.g.&#xD;
             Systemic Lupus Erythematosis, Scleroderma, or Psoriatic Arthritis)&#xD;
&#xD;
          -  Grade 2 or above leukopenia (i.e. white blood cells &lt; 3000/mm^3 [SI units: &lt; 3.0 x&#xD;
             10^9/L)&#xD;
&#xD;
          -  Thrombocytopenia or thrombocytosis (platelets &gt; 125,000/mm^3 or &gt; 1,000,000/mm^3 [SI&#xD;
             units: &lt; 125 x 10^9/L or &gt; 1,000 x 10^9/L]), respectively.&#xD;
&#xD;
          -  Grade 2 or above liver function abnormality(i.e. total bilirubin .1.5 x the upper&#xD;
             limit of normal; or aspartate aminotransfersate [AST/SGOT] or alanine aminotransferase&#xD;
             [ALT/SGPT]&gt; 2.5 x upper limit of normal.&#xD;
&#xD;
          -  Renal disease (including serum creatinine level &gt; 1.5 x the upper limit of normal).&#xD;
&#xD;
          -  Any history of immunodeficiency syndromes or infection with human immunodeficiency&#xD;
             virus (HIV), or a history of hepatitis C or chronic hepatitis B.&#xD;
&#xD;
          -  Pregnant or breastfeeding women or women planning to become pregnant during the study&#xD;
             or within 4 weeks after the last dose of study drug.&#xD;
&#xD;
          -  Any major surgery, including joint surgery, within 3 months before the screening&#xD;
             visit.&#xD;
&#xD;
          -  Scheduled elective surgery during the study participation.&#xD;
&#xD;
          -  Participated in any previous clinical trial using MM-093 or have any prior exposure to&#xD;
             MM-093.&#xD;
&#xD;
          -  History of severe hypersensitivity to goat, sheep, or cow milk. (Patients who are&#xD;
             lactose intolerant are not excluded).&#xD;
&#xD;
          -  Any other condition that the investigator feels would jeopardize the integrity of the&#xD;
             study (e.g. a CTCAE grade 2 or above clinical finding or laboratory result).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montgomery Rheumatology Associates</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Valley Rheumatology &amp; Osteoporosis</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Medical Center of the Central Coast</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddock Park Clinical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research of Florida, Inc.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Bone &amp; Joint Institute</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wichita Clinic</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of Nebraska</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of Reno</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center and Carolina Bone and Joint</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Pennsylvania Rheumatology Association</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Internal Medicine</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Division of Rheumatology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>April 5, 2007</study_first_submitted>
  <study_first_submitted_qc>April 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2007</study_first_posted>
  <last_update_submitted>March 24, 2008</last_update_submitted>
  <last_update_submitted_qc>March 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2008</last_update_posted>
  <responsible_party>
    <organization>Merrimack Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

